Special channel feed – Endpoints News

Special channel feed

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

7 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2018

7 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

7 years ago

The under-40s: How does the next generation of biopharma executives view the future?

8 years ago

Elephants can't jump? IDEA's Mike Rea says some Big Pharma players are crushing old beliefs

8 years ago

12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you

8 years ago

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

8 years ago

Top 10 pipeline blowups, setbacks and snafus in H2 2017

8 years ago

Where the money is: Top 100 VCs investing in US biotechs during 2017

8 years ago

Video: How many PD-1/L1 drugs do we need? Where is immunotherapy headed? Watch Jay Bradner, Hervé Hoppenot, Ellen Sigal, David Berman, Gideon Blumenthal, and Aiman Shalabi discuss with Endpoints at #JPM18

8 years ago

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

8 years ago

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

8 years ago

Analysts’ top 10 biotech takeover targets are concentrated in two key areas

8 years ago

The top 10 biopharma CROs in the world—mid-2017 edition

8 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2017

8 years ago

The 15 top R&D spenders in the global biopharma business: 2016

9 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2016

9 years ago

Where the money is: Biotech’s megahubs command VC's billions

9 years ago

These 300(+) Biotech Twitter citizens are the quickest to tweet news

9 years ago

First page Previous page 1 2 34